MountView Therapeutics is a biopharmaceutical company developing next generation transformative technologies for gene and drug delivery targeting vascular endothelium to treat human diseases.
Transformative endothelium-targeted regulatable gene therapy: Precise and Effective
The proprietary nanoparticle delivery platform is the next generation small molecule and gene delivery technology targeting the vascular endothelium without gene size limitation. It can deliver CRISPR/Cas9 and other genome editors, and any transgene(s) in a regulatable, organ and cell-specific manner, and modulate the expression of multiple genes simultaneously for treatment of various diseases caused by endothelial dysfunction including cardiovascular diseases, hypertension, pulmonary arterial hypertension, severe sepsis, acute respiratory distress syndrome, cancer, and cancer metastasis.
Precision gene therapy makes one's endothelium forever young and rejuvenates aged endothelium for healthy life
The biotech team also provides nanoparticle products for rapid robust gene expression modulation (knockout and/or overexpresison of 1-5 genes simultaneously) selectively in vascular endothelial cells in mice and rats at any ages. It can modulate gene expression in a regulatable, organ and cell-specific manner.
Make single or double knockout mice as quick as a week instead of 1-2 years